基于循证医学证据发现钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在治疗T2DM合并心血管疾病方面的获益逐渐显现,但其具体机制还不明确.本文通过检索PubMed、Web of Science、中国知网(CNKI)等数据库,选定T2DM合并射血分数保留型心力衰竭(HFpEF),通过整理T2DM致HFpEF的病理机制以及SGLT2i的药理机制,总结归纳SGLT2i有益于治疗心力衰竭的机制.同时,本文结合循证医学,进一步探讨SGLT2i在临床应用中的现状及未来展望.
Research status of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes mellitus with heart failure with preserved ejection fraction
Sodium-glucose co-transporter protein 2 inhibitor(SGLT2i)has steadily demonstrated benefits in the treatment of type 2 diabetes complicated with cardiovascular diseases based on evidence-based medicine,but its precise mechanism is yet unknown.We identified type 2 diabetes patients with HFpEF by searching PubMed,Web of Science,China knowledge network(CNKI),and other databases.We then summarized the pathological mechanism of HFpEF caused by type 2 diabetes.At the same time,to link to evidence-based medical,we explored the future of SGLT2i in clinical application.
sodium-glucose co-transporter protein 2 inhibitorheart failure with preserved ejection fractiontype 2 diabetes mellitus
国家科技期刊平台
NSTL
万方数据
